94 related articles for article (PubMed ID: 17981213)
1. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia.
Lahiri O; Harris S; Packham G; Howell M
Cancer Genet Cytogenet; 2007 Nov; 179(1):36-44. PubMed ID: 17981213
[TBL] [Abstract][Full Text] [Related]
2. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
3. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
4. MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.
Willander K; Ungerbäck J; Karlsson K; Fredrikson M; Söderkvist P; Linderholm M
Eur J Haematol; 2010 Sep; 85(3):251-6. PubMed ID: 20491880
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.
Kaderi MA; Mansouri M; Zainuddin N; Cahill N; Gunnarsson R; Jansson M; Kimby E; Aleskog A; Lundin J; Glimelius B; Melbye M; Juliusson G; Jurlander J; Rosenquist R
Leuk Res; 2010 Mar; 34(3):335-9. PubMed ID: 19573916
[TBL] [Abstract][Full Text] [Related]
6. G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression.
Moshynska O; Moshynskyy I; Misra V; Saxena A
Oncogene; 2005 Mar; 24(12):2042-9. PubMed ID: 15688029
[TBL] [Abstract][Full Text] [Related]
7. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
Asslaber D; Piñón JD; Seyfried I; Desch P; Stöcher M; Tinhofer I; Egle A; Merkel O; Greil R
Blood; 2010 May; 115(21):4191-7. PubMed ID: 20089965
[TBL] [Abstract][Full Text] [Related]
8. Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia.
Abo Elwafa R; Abd Elrahman A; Ghallab O
Clin Transl Oncol; 2021 Jan; 23(1):92-99. PubMed ID: 32468342
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive single nucleotide polymorphism study supports the role of MDM2 in p53-competent chronic lymphocytic leukemia.
Lucas DM; Byrd JC
J Clin Oncol; 2008 May; 26(14):2244-5. PubMed ID: 18467712
[No Abstract] [Full Text] [Related]
10. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
11. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
[TBL] [Abstract][Full Text] [Related]
12. Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia.
Isin M; Yenerel M; Aktan M; Buyru N; Dalay N
DNA Cell Biol; 2012 May; 31(5):777-82. PubMed ID: 22047081
[TBL] [Abstract][Full Text] [Related]
13. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated.
Starczynski J; Pepper C; Pratt G; Hooper L; Thomas A; Milligan D; Bentley P; Fegan C
J Clin Oncol; 2005 Mar; 23(7):1514-21. PubMed ID: 15735127
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
[TBL] [Abstract][Full Text] [Related]
15. The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia.
Skogsberg S; Tobin G; Kröber A; Kienle D; Thunberg U; Aleskog A; Karlsson K; Laurell A; Merup M; Vilpo J; Sundström C; Roos G; Jernberg-Wiklund H; Döhner H; Nilsson K; Stilgenbauer S; Rosenquist R
Leukemia; 2006 Jan; 20(1):77-81. PubMed ID: 16307023
[TBL] [Abstract][Full Text] [Related]
16. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.
McGraw KL; Cluzeau T; Sallman DA; Basiorka AA; Irvine BA; Zhang L; Epling-Burnette PK; Rollison DE; Mallo M; Sokol L; Solé F; Maciejewski J; List AF
Oncotarget; 2015 Oct; 6(33):34437-45. PubMed ID: 26416416
[TBL] [Abstract][Full Text] [Related]
17. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
[TBL] [Abstract][Full Text] [Related]
18. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.
Saddler C; Ouillette P; Kujawski L; Shangary S; Talpaz M; Kaminski M; Erba H; Shedden K; Wang S; Malek SN
Blood; 2008 Feb; 111(3):1584-93. PubMed ID: 17971485
[TBL] [Abstract][Full Text] [Related]
20. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]